MA48793A - Procédés de fabrication et d'utilisation d'inhibiteurs de pde9 - Google Patents

Procédés de fabrication et d'utilisation d'inhibiteurs de pde9

Info

Publication number
MA48793A
MA48793A MA048793A MA48793A MA48793A MA 48793 A MA48793 A MA 48793A MA 048793 A MA048793 A MA 048793A MA 48793 A MA48793 A MA 48793A MA 48793 A MA48793 A MA 48793A
Authority
MA
Morocco
Prior art keywords
manufacturing
methods
pde9 inhibitors
pde9
inhibitors
Prior art date
Application number
MA048793A
Other languages
English (en)
Inventor
Yuyin Chen
Jianshe Kong
Rujian Ma
Xiao Meng
Liang Qin
Fenglai Sun
Jikui Sun
Jinxu Sun
Niels Svenstrup
Huanming Xiao
Jun Zhang
Junhua Zhang
Jingyang Zhu
Original Assignee
Imara Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imara Inc filed Critical Imara Inc
Publication of MA48793A publication Critical patent/MA48793A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA048793A 2017-05-26 2018-05-25 Procédés de fabrication et d'utilisation d'inhibiteurs de pde9 MA48793A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762511367P 2017-05-26 2017-05-26

Publications (1)

Publication Number Publication Date
MA48793A true MA48793A (fr) 2020-04-08

Family

ID=64396048

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048793A MA48793A (fr) 2017-05-26 2018-05-25 Procédés de fabrication et d'utilisation d'inhibiteurs de pde9

Country Status (23)

Country Link
US (3) US11370795B2 (fr)
EP (1) EP3630772B1 (fr)
JP (1) JP7609518B2 (fr)
KR (1) KR102627975B1 (fr)
CN (2) CN111183140B (fr)
BR (1) BR112019024877A2 (fr)
CA (1) CA3064004A1 (fr)
DK (1) DK3630772T3 (fr)
EA (1) EA201992721A1 (fr)
ES (1) ES2969895T3 (fr)
FI (1) FI3630772T3 (fr)
HR (1) HRP20240146T1 (fr)
HU (1) HUE065158T2 (fr)
IL (1) IL270792B2 (fr)
LT (1) LT3630772T (fr)
MA (1) MA48793A (fr)
MX (2) MX2019014049A (fr)
PL (1) PL3630772T3 (fr)
PT (1) PT3630772T (fr)
RS (1) RS65143B1 (fr)
SI (1) SI3630772T1 (fr)
TW (2) TWI843393B (fr)
WO (1) WO2018218104A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053968T2 (hu) 2015-07-07 2021-08-30 H Lundbeck As Triazinon vázzal és imidazo-pirazinon vázzal rendelkezõ PDE9 inhibitorok perifériás betegségek kezelésére
US11370795B2 (en) 2017-05-26 2022-06-28 Imara Inc. Process for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
DK3801526T3 (da) 2018-05-25 2024-03-25 Cardurion Pharmaceuticals Inc Monohydrate og krystallinske former af 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imidazo[1,5-a]pyrazin-8-on
KR20250108770A (ko) 2018-08-31 2025-07-15 카듀리온 파마슈티칼스, 인크. 겸상 세포 질환의 치료를 위한 pde9 억제제
CN109734653B (zh) * 2019-02-21 2020-07-14 北京悦康科创医药科技股份有限公司 一种阿加曲班起始原料异构体杂质的拆分方法
WO2020202183A1 (fr) * 2019-03-29 2020-10-08 Mylan Laboratories Limited Procédé de préparation d'upadacitinib et de ses intermédiaires
JP2022527630A (ja) * 2019-04-05 2022-06-02 イマラ インク. 鎌状赤血球症を治療するためのpde9阻害剤
WO2022036111A1 (fr) * 2020-08-13 2022-02-17 Imara Inc. Méthodes et compositions pour le traitement de la maladie à hématies falciformes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2152412T3 (es) 1994-08-08 2001-02-01 Debiopharm Sa Preparacion farmaceuticamente estable de oxaliplatino.
US20040220078A1 (en) 2001-03-02 2004-11-04 Houssam Ibrahim Device for packaging an oxaliplatinum solution
JP2005508978A (ja) * 2001-11-02 2005-04-07 ファイザー・プロダクツ・インク Pde9阻害薬によるインスリン抵抗性症候群及び2型糖尿病の治療
AU2003284885A1 (en) 2002-10-21 2004-05-13 Kensey Nash Corporation Device and methods for sequential, regional delivery of multiple cytotoxic agents
GB0522569D0 (en) 2005-11-04 2005-12-14 Univ Bath Biocompatible drug delivery device
ES2377849T3 (es) 2007-05-11 2012-04-02 Pfizer Inc. Compuestos amino-heterocíclicos
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
RU2603140C2 (ru) 2010-09-20 2016-11-20 Айронвуд Фармасьютикалз, Инк. Соединения имидазотриазинона
JP2015531401A (ja) 2011-10-10 2015-11-02 ハー・ルンドベック・アクチエゼルスカベット イミダゾピラジノン骨格を有するpde9i
MX351582B (es) 2012-01-26 2017-10-20 H Lundbeck As Inhibidores de pde9 con estructura basica de imidazotriazinona.
US10058688B2 (en) 2012-05-09 2018-08-28 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
MX365688B (es) 2012-08-31 2019-06-11 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
EP2983730B1 (fr) 2013-04-10 2019-10-16 Massachusetts Institute of Technology Dispositifs et procédés d'administration de médicament locale pour traiter un cancer
US10369340B2 (en) 2013-08-12 2019-08-06 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
HUE053968T2 (hu) * 2015-07-07 2021-08-30 H Lundbeck As Triazinon vázzal és imidazo-pirazinon vázzal rendelkezõ PDE9 inhibitorok perifériás betegségek kezelésére
US11370795B2 (en) 2017-05-26 2022-06-28 Imara Inc. Process for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one

Also Published As

Publication number Publication date
SI3630772T1 (sl) 2024-05-31
US20250019381A1 (en) 2025-01-16
JP2020527535A (ja) 2020-09-10
WO2018218104A1 (fr) 2018-11-29
ES2969895T3 (es) 2024-05-23
IL270792A (en) 2020-01-30
HUE065158T2 (hu) 2024-05-28
EA201992721A1 (ru) 2020-09-10
IL270792B1 (en) 2023-09-01
CA3064004A1 (fr) 2018-11-29
PT3630772T (pt) 2024-02-05
KR102627975B1 (ko) 2024-01-19
HRP20240146T1 (hr) 2024-04-12
EP3630772A4 (fr) 2021-01-13
US11370795B2 (en) 2022-06-28
MX2019014049A (es) 2020-07-28
CN111183140A (zh) 2020-05-19
US11999741B2 (en) 2024-06-04
EP3630772A1 (fr) 2020-04-08
DK3630772T3 (da) 2024-02-05
RS65143B1 (sr) 2024-02-29
LT3630772T (lt) 2024-02-26
CN111183140B (zh) 2022-12-02
EP3630772B1 (fr) 2023-11-01
KR20200016891A (ko) 2020-02-17
TWI791021B (zh) 2023-02-01
JP7609518B2 (ja) 2025-01-07
CN115746003A (zh) 2023-03-07
FI3630772T3 (fi) 2024-01-31
TW202334156A (zh) 2023-09-01
MX2023000191A (es) 2023-02-09
CN115746003B (zh) 2024-08-09
US20200157108A1 (en) 2020-05-21
US20230183244A1 (en) 2023-06-15
IL270792B2 (en) 2024-01-01
TWI843393B (zh) 2024-05-21
TW201908319A (zh) 2019-03-01
PL3630772T3 (pl) 2024-08-05
BR112019024877A2 (pt) 2020-06-09

Similar Documents

Publication Publication Date Title
EP3827627A4 (fr) Stations de base et procédés associés
MA48793A (fr) Procédés de fabrication et d'utilisation d'inhibiteurs de pde9
EP3600318A4 (fr) Procédés d'utilisation d'inhibiteurs d'ehmt2
EP3827613A4 (fr) Stations de base et procédés associés
EP3775196A4 (fr) Procédés de génération de nanoréseaux et de microréseaux
EP3823673A4 (fr) Compositions anti-cd112r et procédés
EP3368538A4 (fr) Inhibiteurs de la kinase wee 1 et leurs procédés de fabrication et d'utilisation
EP3515879A4 (fr) Équipement de durcissement avancé et procédés d'utilisation de celui-ci
MA43802A (fr) Matières cellulosiques et procédés de fabrication et d'utilisation de celles-ci
EP3867936A4 (fr) Éponges nano-graphitiques et leurs procédés de fabrication
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
EP3645048A4 (fr) Anticorps multispécifiques et procédés de fabrication et d'utilisation associés
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
EP3863417A4 (fr) Distributeur de granité et procédés de distribution de granité
EP3494213A4 (fr) Modèle de barrière hémato-encéphalique et procédés de fabrication et d'utilisation de ce dernier
EP3688132A4 (fr) Solutions de décapage et procédés d'utilisation de solutions de décapage
EP3510040A4 (fr) Inhibiteurs d'éctonucléotidase et leurs procédés d'utilisation
EP3689876A4 (fr) Inhibiteur de pde9 et son utilisation
MA45094A (fr) Matériaux souples antidérapants et procédés pour leur fabrication et leur utilisation
EP3336091A4 (fr) Inhibiteur d'irak4 et son utilisation
EP3710430A4 (fr) Inhibiteurs d'acss2 et leurs procédés d'utilisation
EP3307321A4 (fr) Plate-forme d'anticorps multi-spécifiques et procédés associés
EP3635000A4 (fr) Manabodies et procédés d'utilisation
MA41296A (fr) Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
EP3426262A4 (fr) Agents de réticulation et procédés associés